| Dr Travis Goff, PHARMD | |
|
501 Commercial Dr, Bonner Springs, KS 66012-9617 | |
| (913) 422-1040 | |
| Not Available |
| Full Name | Dr Travis Goff |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 501 Commercial Dr, Bonner Springs, Kansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417544784 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 1-14102 (Kansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Travis Goff, PHARMD 501 Commercial Dr, Bonner Springs, KS 66012-9617 Ph: (913) 422-1040 | Dr Travis Goff, PHARMD 501 Commercial Dr, Bonner Springs, KS 66012-9617 Ph: (913) 422-1040 |
News Archive
A healthcare gap amounting to a ‘death sentence' for Cystic Fibrosis (CF) children born in Eastern Europe must be closed say researchers from the EuroCareCF Coordination Action for Cystic Fibrosis.
The Wall Street Journal: "More employers are scrutinizing employees' health-insurance dependents in order to weed out ineligible beneficiaries" in an effort to cut costs. "Benefits-consulting companies say interest in dependent audits has been growing for the past few years, but has ticked up more recently. … These companies aim to verify the relationships of dependents such as spouses and children, soliciting documents including marriage and birth certificates. In many cases, employers haven't previously asked employees to verify dependents' eligibility" (Mattioli, 11/22).
IDEV(R) Technologies, Incorporated, (IDEV) an emerging leader in the development and marketing of minimally invasive medical technologies, today announced that the first patient was enrolled in the Company's FDA-approved multi-center clinical trial of its self-expanding SUPERA(R) stent, a novel stent platform designed for the treatment of biliary and peripheral artery disease (PAD) in the superficial femoral artery (SFA).
ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to its IMGN901 compound when used for the treatment of Merkel cell carcinoma (MCC). Through a separate process, the European Union (EU) Committee for Orphan Medicinal Products (COMP) concurrently also granted IMGN901 orphan medicinal product designation for the treatment of MCC.
Inhibitex, Inc. today reported top-line safety and efficacy data from its Phase II clinical trial of FV-100, an oral antiviral compound being developed to treat herpes zoster, more commonly referred to as shingles. The study was the first clinical trial to assess the antiviral activity of FV-100, included 350 shingles patients and compared two once-daily doses of FV-100 (200 mg and 400 mg) to an active control, valacyclovir, one of the most commonly-used antiviral drugs to treat shingles.
› Verified 9 days ago
Christine Colleen Wachter, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 12801 Kansas Ave, Bonner Springs, KS 66012 Phone: 913-441-8800 | |
Anqi Li, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 550 S 129th St, Bonner Springs, KS 66012 Phone: 913-543-5001 | |
Sandy Arjon, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 501 Commercial Dr, Bonner Springs, KS 66012 Phone: 913-422-1040 | |
Nicoline Nge-nkeng, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 550 S 129th St, Bonner Springs, KS 66012 Phone: 913-543-5001 Fax: 913-543-5007 | |
Zernain Naeem Qaisar, PHARMACIST Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 501 Commercial Dr, Bonner Springs, KS 66012 Phone: 913-422-4140 | |
Sunni Shelton, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 12801 Kansas Ave, Bonner Springs, KS 66012 Phone: 913-441-8800 Fax: 913-441-8801 |